Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eledon Pharmaceuticals, Inc. - Common Stock
(NQ:
ELDN
)
1.485
-0.025 (-1.66%)
Streaming Delayed Price
Updated: 12:42 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eledon Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
Next >
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
December 01, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
November 18, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
November 14, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
November 11, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
November 06, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
November 05, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
October 17, 2025
Conference call and webcast to discuss results to be held on November 7, 2025 at 8:00 a.m. ET
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
September 24, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
August 29, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
August 14, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
August 06, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
July 30, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
July 17, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
June 25, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
May 14, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
March 20, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
March 04, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
February 07, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
January 13, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
November 12, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
November 06, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
David-Alexandre (‘DA’) Gros, CEO of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN), to Present at NobleCon20
November 06, 2024
Via
Investor Brand Network
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
October 29, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
October 29, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
September 11, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
September 04, 2024
Enrollment Completed Four Months Ahead of Schedule
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
August 14, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
July 29, 2024
80 Participants (Two-thirds of Projected Recruitment) Enrolled
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
